The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis?
Abstract
Multiple sclerosis is affecting approximately 1 out of every 1000 individuals in the western world. After axons are denuded of myelin in the early stages of the disease, remyelination occurs, but eventually this process fails, and permanent disability is the result. During development, the polysialylated form of the neural cell adhesion molecule NCAM, PSA-NCAM, is expressed at the axonal surface and acts as a negative regulator of myelination, presumably by preventing myelin-forming cells from attaching to the axon. Removal of PSA-NCAM from the axonal surface is a prerequisite for the initiation of myelination. We questioned whether, in multiple sclerosis, re-expression of PSA-NCAM by axons could occur, and therefore account for the failure of remyelination. Forty multiple sclerosis lesions from 24 different post-mortem multiple sclerosis cases were selected by histological methods and analysed by immunohistochemistry. Demyelinated lesions and partially remyelinated lesions (shadow plaques) were studied. Controls consisted of post-mortem brain tissue from patients with amyotrophic lateral sclerosis and without neurological disease. We showed that PSA-NCAM, normally absent from adult brain, is re-expressed on demyelinated axons in the plaques. Within shadow plaques, remyelinated axons do not express PSA-NCAM. Re-expression of PSA-NCAM could act as an inhibitor of remyelination and participate in disease progression in multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Dobson, R., & Giovannoni, G. (2019) · European Journal of Neurology · doi:10.1111/ene.13819 · Cited by 2,148
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
Progressive cerebral atrophy in multiple sclerosis A serial MRI study
Losseff, N. A., Wang, L., Lai, H. M., Yoo, D. S., Gawne-Cain, M. L., McDonald, W. I., Miller, D. H., & Thompson, A. J. (1996) · Brain · doi:10.1093/brain/119.6.2009 · Cited by 479
A quantitative analysis of oligodendrocytes in multiple sclerosis lesions
Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., & Lassmann, H. (1999) · Brain · doi:10.1093/brain/122.12.2279 · Cited by 464
Evangelou, N. (2000) · Brain · doi:10.1093/brain/123.9.1845 · Cited by 416
Fannon, A. M., & Colman, D. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80175-0 · Cited by 406
Seki, T., & Arai, Y. (1993) · Neuroscience Research · doi:10.1016/0168-0102(93)90111-3 · Cited by 397
Axonal changes in chronic demyelinated cervical spinal cord plaques
Lovas, G., Szilagyi, N., Majtenyi, K., Palkovits, M., & Komoly, S. (2000) · Brain · doi:10.1093/brain/123.2.308 · Cited by 356
Cited by
ADULT NEUROGENESIS IN THE MAMMALIAN CENTRAL NERVOUS SYSTEM
Ming, G.-L., & Song, H. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.051804.101459 · Cited by 1,839
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Oligodendrocytes: biology and pathology
Bradl, M., & Lassmann, H. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0601-5 · Cited by 933
Kuhlmann, T., Miron, V., Cuo, Q., Wegner, C., Antel, J., & Bruck, W. (2008) · Brain · doi:10.1093/brain/awn096 · Cited by 864
Why does remyelination fail in multiple sclerosis?
Franklin, R. J. M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn917 · Cited by 837
Remyelination is extensive in a subset of multiple sclerosis patients
Patrikios, P., Stadelmann, C., Kutzelnigg, A., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., Bruck, W., Lucchinetti, C., & Lassmann, H. (2006) · Brain · doi:10.1093/brain/awl217 · Cited by 807
Schnaar, R. L., Gerardy-Schahn, R., & Hildebrandt, H. (2014) · Physiological Reviews · doi:10.1152/physrev.00033.2013 · Cited by 745
Mechanisms of axon ensheathment and myelin growth
Sherman, D. L., & Brophy, P. J. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1743 · Cited by 668
“This is of particular relevance in the context of demyelinating diseases such as MULTIPLE SCLEROSIS , for which it has been proposed that changes in the expression of proteins on the axonal surface might make axons less susceptible to remyelinatio”
BackgroundTaupin, P. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.08.002 · Cited by 645
Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS
Fancy, S. P. J., Baranzini, S. E., Zhao, C., Yuk, D.-I., Irvine, K.-A., Kaing, S., Sanai, N., Franklin, R. J. M., & Rowitch, D. H. (2009) · Genes & Development · doi:10.1101/gad.1806309 · Cited by 618
Polysialic acid in the plasticity of the developing and adult vertebrate nervous system
Rutishauser, U. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2285 · Cited by 584
Shen, S., Sandoval, J., Swiss, V. A., Li, J., Dupree, J., Franklin, R. J. M., & Casaccia-Bonnefil, P. (2008) · Nature Neuroscience · doi:10.1038/nn.2172 · Cited by 481
Remyelination in multiple sclerosis
Piaton, G., Williams, A., Seilhean, D., & Lubetzki, C. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17530-1 · Cited by 441
PSA-NCAM in mammalian structural plasticity and neurogenesis
Bonfanti, L. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.08.003 · Cited by 438
Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned
Gudi, V., Gingele, S., Skripuletz, T., & Stangel, M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00073 · Cited by 430
“It is still not clear why remyelination fails in MS and a number of putative inhibitors of myelination such as LINGO-1, Notch-Jagged, and PSA-NCAM are frequently accused (Wang et al., 1998a; Charles et al., 2002; Mi et al., 2005) .”
BackgroundWoodruff, R. H., Fruttiger, M., Richardson, W. D., & Franklin, R. J. M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.10.014 · Cited by 335
Oligodendrocyte development and the onset of myelination in the human fetal brain
Jakovcevski, I. (2009) · Frontiers in Neuroanatomy · doi:10.3389/neuro.05.005.2009 · Cited by 323
Activation of the subventricular zone in multiple sclerosis: Evidence for early glial progenitors
Nait-Oumesmar, B., Picard-Riera, N., Kerninon, C., Decker, L., Seilhean, D., Höglinger, G. U., Hirsch, E. C., Reynolds, R., & Baron-Van Evercooren, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606835104 · Cited by 322
Myelin Regeneration: A Recapitulation of Development?
Fancy, S. P. J., Chan, J. R., Baranzini, S. E., Franklin, R. J. M., & Rowitch, D. H. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113629 · Cited by 320
Pathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
Mi, S., Miller, R. H., Tang, W., Lee, X., Hu, B., Wu, W., Zhang, Y., Shields, C. B., Zhang, Y., Miklasz, S., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21581 · Cited by 300
Durrenberger, P. F., Ettorre, A., Kamel, F., Webb, L. V., Sim, M., Nicholas, R. S., Malik, O., Reynolds, R., Boyton, R. J., & Altmann, D. M. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-1 · Cited by 287
Remyelination therapies: a new direction and challenge in multiple sclerosis
Plemel, J. R., Liu, W.-Q., & Yong, V. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.115 · Cited by 281
Mishra, A., Singh, S., & Shukla, S. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518779829 · Cited by 276
Cortical remyelination: A new target for repair therapies in multiple sclerosis
Chang, A., Staugaitis, S. M., Dutta, R., Batt, C. E., Easley, K. E., Chomyk, A. M., Yong, V. W., Fox, R. J., Kidd, G. J., & Trapp, B. D. (2012) · Annals of Neurology · doi:10.1002/ana.23693 · Cited by 216
Baer, A. S., Syed, Y. A., Kang, S. U., Mitteregger, D., Vig, R., ffrench-Constant, C., Franklin, R. J. M., Altmann, F., Lubec, G., & Kotter, M. R. (2009) · Brain · doi:10.1093/brain/awn334 · Cited by 211
“A number of potential inhibitors have been proposed including axonal PSA-NCAM in chronically demyelinated lesions (Charles et al., 2002), astrocytic hyaluronan (Back et al., 2005) and notch-jagged (John et al., 2002) signalling, although these are not always supported by functional studies in…”
Mechanisms of white matter damage in multiple sclerosis
Lassmann, H. (2014) · Glia · doi:10.1002/glia.22597 · Cited by 191
The translational biology of remyelination: past, present, and future
Franklin, R. J. M., & Gallo, V. (2014) · Glia · doi:10.1002/glia.22622 · Cited by 162
Inhibition of CNS Remyelination by the Presence of Semaphorin 3A
Syed, Y. A., Hand, E., Möbius, W., Zhao, C., Hofer, M., Nave, K. A., & Kotter, M. R. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4930-10.2011 · Cited by 134
Remyelinating strategies for the treatment of multiple sclerosis
Stangel, M., & Hartung, H.-P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00105-3 · Cited by 126
Polysialic acid in brain development and synaptic plasticity
Hildebrandt, H., & Dityatev, A. (2013) · Topics in current chemistry · doi:10.1007/128_2013_446 · Cited by 94
Kipp, M., Gingele, S., Pott, F., Clarner, T., van der Valk, P., Denecke, B., Gan, L., Siffrin, V., Zipp, F., Dreher, W., et al. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.003 · Cited by 83
Role and therapeutic implications of protein glycosylation in neuroinflammation
Rebelo, A. L., Chevalier, M. T., Russo, L., & Pandit, A. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.01.004 · Cited by 50
Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination
Syed, Y. A., Zhao, C., Mahad, D., Möbius, W., Altmann, F., Foss, F., Sentürk, A., Acker-Palmer, A., Lubec, G., Lilley, K., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1521-1 · Cited by 50
Brain lipid binding protein (FABP7) as modulator of astrocyte function
KIPP, M., CLARNER, T., GINGELE, S., POTT, F., AMOR, S., VAN DER VALK, P., & BEYER, C. (2011) · Physiological Research · doi:10.33549/physiolres.932168 · Cited by 42
Remyelination in the central nervous system
Franklin, R. J. M., Bodini, B., & Goldman, S. A. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041371 · Cited by 40
Koutsoudaki, P. N., Hildebrandt, H., Gudi, V., Skripuletz, T., Škuljec, J., & Stangel, M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.070 · Cited by 37
Vereyken, E. J. F., Fluitsma, D. M., Bolijn, M. J., Dijkstra, C. D., & Teunissen, C. E. (2009) · Glia · doi:10.1002/glia.20852 · Cited by 33
Remyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22
TGFβ signaling mediates microglial resilience to spatiotemporally restricted myelin degeneration
Zhu, K., Liu, Y., Min, J.-H., Joshua, V., Lin, J., Li, Y., Kreutzmann, J. C., Guo, Y., Xia, W., Mohammadi, E., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-025-02161-4 · Cited by 11
Schröder, L.-J., Thiesler, H., Gretenkort, L., Möllenkamp, T. M., Stangel, M., Gudi, V., & Hildebrandt, H. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1207540 · Cited by 10
Metadata
- Authors
- Charles, P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-09-01
- Volume
- 125
- Issue
- 9
- Pages
- 1972-1979
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2118746021
- Cited by
- 288
- References
- 35
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.